Otsuka Holdings Co., Ltd. - Product Pipeline Review - 2015

  • ID: 3266309
  • Company Profile
  • 98 pages
  • Global Markets Direct
1 of 4
Otsuka Holdings Co., Ltd. - Product Pipeline Review - 2015

Summary

This, ‘Otsuka Holdings Co., Ltd. - Product Pipeline Review - 2015’, provides an overview of the Otsuka Holdings Co., Ltd.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Otsuka Holdings Co., Ltd.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Otsuka Holdings Co., Ltd. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Otsuka Holdings Co., Ltd.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Otsuka Holdings Co., Ltd.’s pipeline products

Reasons to buy

- Evaluate Otsuka Holdings Co., Ltd.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Otsuka Holdings Co., Ltd. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Otsuka Holdings Co., Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Otsuka Holdings Co., Ltd. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Otsuka Holdings Co., Ltd.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Otsuka Holdings Co., Ltd. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables
List of Figures
Otsuka Holdings Co., Ltd. Snapshot
Otsuka Holdings Co., Ltd. Overview
Key Information
Key Facts
Otsuka Holdings Co., Ltd. - Research and Development Overview
Key Therapeutic Areas
Otsuka Holdings Co., Ltd. - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Combination Treatment Modalities
Pipeline Products - Partnered Products
Partnered Products/Combination Treatment Modalities
Otsuka Holdings Co., Ltd. - Pipeline Products Glance
Otsuka Holdings Co., Ltd. - Late Stage Pipeline Products
Pre-Registration Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
Otsuka Holdings Co., Ltd. - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Otsuka Holdings Co., Ltd. - Drug Profiles
(tipiracil hydrochloride + trifluridine)
Product Description
Mechanism of Action
R&D Progress
aripiprazole
Product Description
Mechanism of Action
R&D Progress
brexpiprazole
Product Description
Mechanism of Action
R&D Progress
tolvaptan
Product Description
Mechanism of Action
R&D Progress
trabectedin
Product Description
Mechanism of Action
R&D Progress
(aripiprazole + sertraline)
Product Description
Mechanism of Action
R&D Progress
(carteolol hydrochloride + latanoprost)
Product Description
Mechanism of Action
R&D Progress
delamanid
Product Description
Mechanism of Action
R&D Progress
nabiximols
Product Description
Mechanism of Action
R&D Progress
rebamipide
Product Description
Mechanism of Action
R&D Progress
(dextromethorphan hydrobromide + quinidine sulfate)
Product Description
Mechanism of Action
R&D Progress
AVP-786
Product Description
Mechanism of Action
R&D Progress
OCV-101
Product Description
Mechanism of Action
R&D Progress
OCV-501
Product Description
Mechanism of Action
R&D Progress
OPA-15406
Product Description
Mechanism of Action
R&D Progress
probucol
Product Description
Mechanism of Action
R&D Progress
tetomilast
Product Description
Mechanism of Action
R&D Progress
OPA-6566
Product Description
Mechanism of Action
R&D Progress
OPB-111001
Product Description
Mechanism of Action
R&D Progress
OPB-31121
Product Description
Mechanism of Action
R&D Progress
LPC-01
Product Description
Mechanism of Action
R&D Progress
OCVC-02
Product Description
Mechanism of Action
R&D Progress
OPB-111077
Product Description
Mechanism of Action
R&D Progress
OPB-51602
Product Description
Mechanism of Action
R&D Progress
OPC-108459
Product Description
Mechanism of Action
R&D Progress
OPS-2071
Product Description
Mechanism of Action
R&D Progress
Otsuka Holdings Co., Ltd. - Pipeline Analysis
Otsuka Holdings Co., Ltd. - Pipeline Products by Target
Otsuka Holdings Co., Ltd. - Pipeline Products by Route of Administration
Otsuka Holdings Co., Ltd. - Pipeline Products by Molecule Type
Otsuka Holdings Co., Ltd. - Pipeline Products by Mechanism of Action
Otsuka Holdings Co., Ltd. - Recent Pipeline Updates
Otsuka Holdings Co., Ltd. - Dormant Projects
Otsuka Holdings Co., Ltd. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
(tipiracil hydrochloride + trifluridine)
AVP-13358
AZD-2479
rebamipide
Otsuka Holdings Co., Ltd. - Company Statement
Otsuka Holdings Co., Ltd. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Otsuka Holdings Co., Ltd., Key Information
Otsuka Holdings Co., Ltd., Key Facts
Otsuka Holdings Co., Ltd. - Pipeline by Indication, 2015
Otsuka Holdings Co., Ltd. - Pipeline by Stage of Development, 2015
Otsuka Holdings Co., Ltd. - Monotherapy Products in Pipeline, 2015
Otsuka Holdings Co., Ltd. - Combination Treatment Modalities in Pipeline, 2015
Otsuka Holdings Co., Ltd. - Partnered Products in Pipeline, 2015
Otsuka Holdings Co., Ltd. - Partnered Products/ Combination Treatment Modalities, 2015
Otsuka Holdings Co., Ltd. - Pre-Registration, 2015
Otsuka Holdings Co., Ltd. - Phase III, 2015
Otsuka Holdings Co., Ltd. - Phase II, 2015
Otsuka Holdings Co., Ltd. - Phase I, 2015
Otsuka Holdings Co., Ltd. - Pipeline by Target, 2015
Otsuka Holdings Co., Ltd. - Pipeline by Route of Administration, 2015
Otsuka Holdings Co., Ltd. - Pipeline by Molecule Type, 2015
Otsuka Holdings Co., Ltd. - Pipeline Products by Mechanism of Action, 2015
Otsuka Holdings Co., Ltd. - Recent Pipeline Updates, 2015
Otsuka Holdings Co., Ltd. - Dormant Developmental Projects,2015
Otsuka Holdings Co., Ltd. - Discontinued Pipeline Products, 2015
Otsuka Holdings Co., Ltd., Other Locations
Otsuka Holdings Co., Ltd., Subsidiaries

List of Figures
Otsuka Holdings Co., Ltd. - Pipeline by Top 10 Indication, 2015
Otsuka Holdings Co., Ltd. - Pipeline by Stage of Development, 2015
Otsuka Holdings Co., Ltd. - Monotherapy Products in Pipeline, 2015
Otsuka Holdings Co., Ltd. - Combination Treatment Modalities in Pipeline, 2015
Otsuka Holdings Co., Ltd. - Partnered Products in Pipeline, 2015
Otsuka Holdings Co., Ltd. - Pipeline by Top 10 Target, 2015
Otsuka Holdings Co., Ltd. - Pipeline by Top 10 Route of Administration, 2015
Otsuka Holdings Co., Ltd. - Pipeline by Top 10 Molecule Type, 2015
Otsuka Holdings Co., Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2015
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll